A randomized, double-blind, placebo-controlled trial examined the cardiometabolic effects of combined levothyroxine (LT4) and liothyronine (LT3) therapy versus LT4 alone in athyreotic patients without cardiovascular risk factors. The study included 38 patients with postsurgical hypothyroidism, of whom 24 completed one year of treatment. The LT4+LT3 group demonstrated a significant improvement
